John F Forbes
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
Bartlett J, Rea D, Dowsett M, Cuzick J, Viale G, Forbes J, Brookes C, Van de Velde C, Putter H, Seynaeve C, Thürlimann B, Dell'Orto P, Mallon E, Sestak I, Regan M, Ahmed I. HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer 2017; 79:129-138.
May 8, 2017HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2
May 8, 2017Eur J Cancer 2017; 79:129-138
Bartlett John M S, Rea Daniel W, Dowsett Mitchell, Cuzick Jack, Viale Giuseppe, Forbes John F, Brookes Cassandra L, Van de Velde Cornelis J H, Putter Hein, Seynaeve Caroline, Thürlimann Beat, Dell'Orto Patrizia, Mallon Elizabeth A, Sestak Ivana, Regan Meredith M, Ahmed Ikhlaaq
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Chirgwin J, Colleoni M, Láng I, Neven P, Forbes J, Rabaglio M, Smith I, Goldhirsch A, Gelber R, Debled M, Ejlertsen B, Price K, Coates A, Giobbie-Hurder A, Thürlimann B. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. J Clin Oncol 2016; 34:2452-9.
May 23, 2016Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
May 23, 2016J Clin Oncol 2016; 34:2452-9
Chirgwin Jacquie H, Colleoni Marco, Láng István, Neven Patrick, Forbes John F, Rabaglio Manuela, Smith Ian, Goldhirsch Aron, Gelber Richard D, Debled Marc, Ejlertsen Bent, Price Karen N, Coates Alan S, Giobbie-Hurder Anita, Thürlimann Beat
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Colleoni M, Coates A, Gelber R, Castiglione M, Gianni L, Thürlimann B, Forbes J, Karlsson P, Price K, Sun Z, Goldhirsch A. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol 2016
Jan 19, 2016Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V
Jan 19, 2016J Clin Oncol 2016
Colleoni Marco, Coates Alan S, Gelber Richard D, Castiglione Monica, Gianni Lorenzo, Thürlimann Beat, Forbes John F, Karlsson Per, Price Karen N, Sun Zhuoxin, Goldhirsch Aron
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Ewertz M, Goldhirsch A, Coates A, Smith I, Láng I, Colleoni M, Gelber R, Rabaglio M, Paridaens R, Forbes J, Bonnefoi H, Thürlimann B, Price K, Ejlertsen B, Regan M, Gray K, Mouridsen H. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol 2012; 30:3967-75.
Oct 8, 2012Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
Oct 8, 2012J Clin Oncol 2012; 30:3967-75
Ewertz Marianne, Goldhirsch Aron, Coates Alan S, Smith Ian E, Láng István, Colleoni Marco, Gelber Richard D, Rabaglio Manuela, Paridaens Robert J, Forbes John F, Bonnefoi Hervé, Thürlimann Beat, Price Karen N, Ejlertsen Bent, Regan Meredith M, Gray Kathryn P, Mouridsen Henning T
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Regan M, BIG 1-98 Collaborative Group, Thürlimann B, Coates A, Gelber R, Price K, Rabaglio M, Wardley A, Láng I, Smith I, Forbes J, Mauriac L, Ejlertsen B, Goldhirsch A, Giobbie-Hurder A, Neven P, International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 2011; 12:1101-8.
Oct 20, 2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
Oct 20, 2011Lancet Oncol 2011; 12:1101-8
Regan Meredith M, BIG 1-98 Collaborative Group, Thürlimann Beat, Coates Alan S, Gelber Richard D, Price Karen N, Rabaglio Manuela, Wardley Andrew, Láng István, Smith Ian, Forbes John F, Mauriac Louis, Ejlertsen Bent, Goldhirsch Aron, Giobbie-Hurder Anita, Neven Patrick, International Breast Cancer Study Group (IBCSG)
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Colleoni M, Coates A, Gelber R, Price K, Wardley A, Pienkowski T, Chirgwin J, Smith I, Láng I, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Regan M, Giobbie-Hurder A, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011; 29:1117-24.
Feb 14, 2011Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
Feb 14, 2011J Clin Oncol 2011; 29:1117-24
Colleoni Marco, Coates Alan S, Gelber Richard D, Price Karen N, Wardley Andrew, Pienkowski Tadeusz, Chirgwin Jacquie, Smith Ian, Láng István, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Regan Meredith M, Giobbie-Hurder Anita, Goldhirsch Aron
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.
Aug 1, 2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Aug 1, 2009Breast Cancer Res Treat 2009; 116:491-500
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Forbes John F, Murray Elizabeth, Fey Martin F, Thürlimann Beat, Lindtner Jurij, Collins John, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Castiglione-Gertsch Monica, Simoncini Edda, Gelber Shari, International Breast Cancer Study Group
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Thürlimann B, Coates A, Castiglione-Gertsch M, Forbes J, Collins J, Colleoni M, Crivellari D, Holmberg S, Gelber R, Price K, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat 2009; 113:137-44.
Jan 1, 2009Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
Jan 1, 2009Breast Cancer Res Treat 2009; 113:137-44
Thürlimann Beat, Coates Alan S, Castiglione-Gertsch Monica, Forbes John F, Collins John, Colleoni Marco, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Goldhirsch Aron
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Crivellari D, Chirgwin J, Smith I, Rabaglio M, Gladieff L, Del Mastro L, Láng I, Colleoni M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Thürlimann B, Price K, Coates A, Sun Z, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. JCO 2008; 26:1972-9.
Apr 20, 2008Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
Apr 20, 2008JCO 2008; 26:1972-9
Crivellari Diana, Chirgwin Jacquie H, Smith Ian E, Rabaglio Manuela, Gladieff Laurence, Del Mastro Lucia, Láng István, Colleoni Marco, Gelber Richard D, Castiglione-Gertsch Monica, Paridaens Robert J, Forbes John F, Mauriac Louis, Mouridsen Henning, Thürlimann Beat, Price Karen N, Coates Alan S, Sun Zhuoxin, Goldhirsch Aron
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Mouridsen H, Price K, Smith I, Colleoni M, Gelber R, Paridaens R, Forbes J, Mauriac L, Thürlimann B, Sun Z, Castiglione-Gertsch M, Rabaglio M, Coates A, Keshaviah A, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. JCO 2007; 25:5715-22.
Dec 20, 2007Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial
Dec 20, 2007JCO 2007; 25:5715-22
Mouridsen Henning, Price Karen N, Smith Ian, Colleoni Marco, Gelber Richard D, Paridaens Robert, Forbes John F, Mauriac Louis, Thürlimann Beat, Sun Zhuoxin, Castiglione-Gertsch Monica, Rabaglio Manuela, Coates Alan S, Keshaviah Aparna, Goldhirsch Aron
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
May 20, 2007The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
May 20, 2007JCO 2007; 25:2019-26
Karlsson Per, Goldhirsch Aron, Gelber Richard D, Forbes John F, Crivellari Diana, Thürlimann Beat, Fey Martin F, Holmberg Stig B, Collins John P, Lindtner Jurij, Murray Elizabeth, Gusterson Barry A, Castiglione-Gertsch Monica, Coates Alan S, Price Karen N, Cole Bernard F, Wallgren Arne
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Coates A, Del Mastro L, Smith I, Chirgwin J, Nogaret J, Pienkowski T, Wardley A, Jakobsen E, Price K, Láng I, Colleoni M, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes J, Paridaens R, Castiglione-Gertsch M, Gelber R, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO 2007; 25:486-92.
Feb 10, 2007Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
Feb 10, 2007JCO 2007; 25:486-92
Coates Alan S, Del Mastro Lucia, Smith Ian, Chirgwin Jacquie, Nogaret Jean-Marie, Pienkowski Tadeusz, Wardley Andrew, Jakobsen Erik H, Price Karen N, Láng István, Colleoni Marco, Keshaviah Aparna, Thürlimann Beat, Mouridsen Henning, Mauriac Louis, Forbes John F, Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D, Goldhirsch Aron
Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Bernhard J, Coates A, Goldhirsch A, Price K, Thürlimann B, Aebi S, Collins J, Murray E, Forbes J, Gelber R, Hürny C, Castiglione-Gertsch M, Zahrieh D, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. JCO 2007; 25:263-70.
Jan 20, 2007Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII
Jan 20, 2007JCO 2007; 25:263-70
Bernhard Jürg, Coates Alan S, Goldhirsch Aron, Price Karen N, Thürlimann Beat, Aebi Stefan, Collins John, Murray Elizabeth, Forbes John F, Gelber Richard D, Hürny Christoph, Castiglione-Gertsch Monica, Zahrieh David, International Breast Cancer Study Group Trial VIII
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Breast International Group (BIG) 1-98 Collaborative Group, Price K, Wardly A, Wardley A, Smith I, Rabaglio M, Gelber R, Castiglione-Gertsch M, Paridaens R, Forbes J, Mauriac L, Mouridsen H, Coates A, Keshaviah A, Thürlimann B, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. NEJM 2005; 353:2747-57.
Dec 29, 2005A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Dec 29, 2005NEJM 2005; 353:2747-57
Breast International Group (BIG) 1-98 Collaborative Group, Price Karen N, Wardly Andrew, Wardley Andrew, Smith Ian, Rabaglio Manuela, Gelber Richard D, Castiglione-Gertsch Monica, Paridaens Robert, Forbes John F, Mauriac Louis, Mouridsen Henning, Coates Alan S, Keshaviah Aparna, Thürlimann Beat, Goldhirsch Aron